Biomimetic Approaches in the Development of Optimised 3D Culture Environments for Drug Discovery in Cardiac Disease DOI Creative Commons
Jennifer H. Shepherd

Biomimetics, Год журнала: 2025, Номер 10(4), С. 204 - 204

Опубликована: Март 26, 2025

Cardiovascular disease remains the leading cause of death worldwide, yet despite massive investment in drug discovery, progress cardiovascular drugs from lab to clinic slow. It is a complex, costly pathway discovery and failure becomes more expensive as progresses along this pathway. The focus has begun shift optimisation vitro culture methodologies, not only because these must be undertaken are earlier on pathway, but also principles 3Rs have become embedded national international legislation regulation. Numerous studies shown myocyte cell behaviour much physiologically relevant 3D compared 2D culture, highlighting advantages using 3D-based models, whether microfluidic or otherwise, for preclinical screening. This review aims provide an overview challenges limitations traditional routes, successes field models discovery. focuses particular role biomimicry can play, around implementation within commercial

Язык: Английский

Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models DOI Creative Commons
Dewald Steyn, Anja Haasbroek‐Pheiffer, Wihan Pheiffer

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(2), С. 195 - 195

Опубликована: Янв. 31, 2025

Drugs administered by means of extravascular routes drug administration must be absorbed into the systemic circulation, which involves movement molecules across biological barriers such as epithelial cells that cover mucosal surfaces or stratum corneum covers skin. Some drugs exhibit poor permeation membranes may experience excessive degradation during first-pass metabolism, tends to limit their bioavailability. Various strategies have been used improve Absorption enhancement include co-administration chemical enhancers, enzymes, and/or efflux transporter inhibitors, changes, and specialized dosage form designs. Models with physiological relevance are needed evaluate efficacy absorption techniques. in vitro cell culture models ex vivo tissue explored quantify effectiveness strategies. This review deliberates on use for evaluation selected including nasal, oromucosal, pulmonary, oral, rectal, transdermal administration.

Язык: Английский

Процитировано

0
Proof of concept for brain organoid-on-a-chip to create multiple domains in forebrain organoids DOI Creative Commons
Yuan‐Chen Tsai, Hajime Ozaki,

Ango Morikawa

и другие.

RSC Advances, Год журнала: 2025, Номер 15(5), С. 3749 - 3755

Опубликована: Янв. 1, 2025

Multilayered microfluidic chips were designed to generate morphogen gradients and topographically organized multi-region forebrain organoids.

Язык: Английский

Процитировано

0
Slightly viscous oxidized alginate dispersions as vehicles for intranasal administration of the α-synuclein aggregation inhibitor Anle 138b in free form or encapsulated in solid lipid nanoparticles DOI
Rosanna Mallamaci, Stefano Castellani, Limosani Francesca

и другие.

International Journal of Pharmaceutics, Год журнала: 2025, Номер 673, С. 125399 - 125399

Опубликована: Фев. 23, 2025

Язык: Английский

Процитировано

0
Microfluidic organ-on-a-chip models for the gut–liver axis: from structural mimicry to functional insights DOI
Weifeng Hu, Yushen Wang,

Junlei Han

и другие.

Biomaterials Science, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

This review discusses advancements in organ-on-a-chip models, emphasizing gut, liver, and integrated gut–liver systems. It covers their applications disease modeling, toxicity testing, drug screening, as well future prospects.

Язык: Английский

Процитировано

0
Biomimetic Approaches in the Development of Optimised 3D Culture Environments for Drug Discovery in Cardiac Disease DOI Creative Commons
Jennifer H. Shepherd

Biomimetics, Год журнала: 2025, Номер 10(4), С. 204 - 204

Опубликована: Март 26, 2025

Cardiovascular disease remains the leading cause of death worldwide, yet despite massive investment in drug discovery, progress cardiovascular drugs from lab to clinic slow. It is a complex, costly pathway discovery and failure becomes more expensive as progresses along this pathway. The focus has begun shift optimisation vitro culture methodologies, not only because these must be undertaken are earlier on pathway, but also principles 3Rs have become embedded national international legislation regulation. Numerous studies shown myocyte cell behaviour much physiologically relevant 3D compared 2D culture, highlighting advantages using 3D-based models, whether microfluidic or otherwise, for preclinical screening. This review aims provide an overview challenges limitations traditional routes, successes field models discovery. focuses particular role biomimicry can play, around implementation within commercial

Язык: Английский

Процитировано

0